MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastric cancer (GC) presents a significant clinical challenge due to its heterogeneity and complex molecular underpinnings.
• MicroRNAs (miRNAs) are implicated in GC, yet specific roles remain largely undefined.
• Identifying novel molecular players is crucial for understanding GC pathogenesis and developing targeted therapies.

Purpose of the Study:

• To discover gastric cancer-specific microRNAs (miRNAs) using next-generation sequencing (NGS).
• To functionally validate the role of identified miRNAs, particularly miR-29c, in gastric cancer.
• To investigate the molecular mechanisms and clinical significance of miR-29c in gastric carcinogenesis.

Main Methods:

• Whole-transcriptome profiling via NGS to identify GC-specific miRNAs in matched tumor and normal tissues.
• Quantitative RT-PCR validation of miR-29c expression in 274 gastric tissue specimens.
• Functional assays in GC cell lines and transgenic mouse models to assess miR-29c's impact on proliferation, invasion, migration, and tumor growth, including target validation.

Main Results:

• NGS identified four GC-specific miRNAs, with miR-29c showing significantly decreased expression in GC tissues.
• Ectopic miR-29c expression in GC cells reduced proliferation, adhesion, invasion, and migration, and suppressed tumor growth in vivo.
• miR-29c directly targets integrin beta 1 (ITGB1), and its expression decreases progressively during gastric carcinogenesis in mouse models.

Conclusions:

• MiR-29c functions as a tumor suppressor in gastric cancer by directly targeting ITGB1.
• The loss of miR-29c expression is an early event in gastric carcinogenesis.
• MiR-29c holds potential as a diagnostic and therapeutic biomarker for gastric cancer patients.